Advanced non-small lung cancer of harbouring EGFR mutations
Conditions
Interventions
1:SBRT
Sponsors
Taizhou Hospital of Zhejiang Province
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: Inclusive criteria: 1) A histopathologically or cytologically proven non-small cell lung cancer(NSCLC) and harbouring EGFR mutations tested by drug resistant gene detection; 2) There were 2~5 lesions that can be measured as RECIST standard; 3) All patients were stage IV,as UICC (Version 8). The maximum diameter of every lung lesion was no more than 5cm; 4) Aged 18 to 85 years old; 5) ECOG was 0 or 1,KPS score > 60; 6) The tumor had not infiltrated into the trachea or the big blood vessels; 7) No patients had received chemotherapy , chest radiotherapy or other biological therapy; 8) Hb=100g/L, Plt=100×10^9/L, NEUT=1.5×10^9/L; 9) SB=1.5×UNLAST (SGOT), ALT (SGPT)=2.5×UNL, ALP=5xUNL; 10) Without uncontrolled lung infection, pleural effusion and interstitial pneumonia; 11) FEV1>0.8L. All patients must sign the consent form.
Exclusion criteria
Exclusion criteria: 1) Lung cancer operation ,chest radiotherapy or chemotherapy was performed,before the study; 2) Patients had psychiatric impairments which will prevent completion of the protocol therapy; 3) Poor compliance of patients.Patients had major medical illnesses which will prevent completion of the protocol therapy; 4) Patients had symptomatic intracranial metastatic tumor; 5)Patients had other uncured malignancies; 6) Three to four allergic reactions to the treatment; 7) Patients had participated in other clinical trials in 30 days; 8) The patients which researchers believed that they should be excluded from this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| progression-free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| overall survival; | — |
Countries
China
Contacts
Public ContactYang Haihua
Taizhou Hospital
Outcome results
None listed